Late-Onset Hypogonadism: The Definitive Guide

What is late-onset hypogonadism?

Late-onset hypogonadism is low testosterone that appears in middle age or later and causes symptoms, most clearly lower sex drive, fewer morning erections and erection problems. It is diagnosed only when those symptoms come together with testosterone that is clearly low on repeated morning blood tests, never from age or a single result. [1], [22], [7]

Hypogonadism means the testes make too little testosterone. The 2008 joint recommendations of five andrology and urology societies defined the late-onset kind as "a clinical and biochemical syndrome associated with advancing age and characterized by symptoms and a deficiency in serum testosterone levels". It is also called age-related hypogonadism, testosterone deficiency syndrome or, informally, "andropause". [1], [23]

The name carries weight:

• US product labels carry a Limitation of Use: safety and efficacy in men with "age-related hypogonadism" (also referred to as "late-onset hypogonadism") have not been established. The FDA describes it as "certain signs and symptoms associated with low blood testosterone levels without a clear cause". [24], [25]
• Some societies say "functional hypogonadism", meaning low testosterone from causes that may reverse, such as obesity. [26], [27]
• The Endocrine Society's July 2026 statement says terms like "age-related", "late-onset" and "functional" hypogonadism "are hard to define operationally and blur the line between treatable disease and normal aging". [7]

In practice, it is the common, age-linked form of low testosterone in which no single disease of the testes or pituitary explains the result. The low testosterone guide covers low testosterone at every age; this guide covers what changes after about 40.

Is "male menopause" real?

Not as a sudden change every man goes through. When the same men are followed over time, testosterone falls by about 1% a year, and very healthy older men showed no average fall. Only about 2 in 100 men aged 40–79 meet the strict definition of late-onset hypogonadism. That is why guidelines say "late-onset" or "age-related hypogonadism" rather than andropause. [8], [9], [2]

How is late-onset hypogonadism diagnosed?

The same way as low testosterone at any age: symptoms or signs, total testosterone below the guideline line on at least two early-morning tests, and tests for the type and cause. Older men get neither a lower nor a higher bar, and US labels require the same two-morning confirmation. [7], [4], [5], [28]

Which symptoms point to it?

Sexual symptoms, most clearly. The European Male Ageing Study (EMAS) surveyed 3,369 men aged 40–79. It found that "only the three sexual symptoms had a syndromic association with decreased testosterone levels": fewer morning erections, low sexual desire and erectile dysfunction. [22]

Symptoms also appear at different levels. In older men at one clinic, loss of sex drive or vigor became more common below 15 nmol/L, depression and type 2 diabetes below 10, and erectile dysfunction only below 8. The authors wrote that "a clear-cut threshold for late-onset hypogonadism was not found". [29]

Tiredness, low mood, poor sleep and belly fat have many causes, and the Endocrine Society says "Symptoms alone are not diagnostic"; see the full symptom list. [7]

Do symptom questionnaires diagnose it?

No. The ADAM questionnaire caught 88% of men with low testosterone but was only 60% specific, so it also flagged about 4 in 10 men with normal levels. The Aging Males' Symptoms scale measures ageing symptoms, not testosterone. The 2008 joint recommendations advise against using either for diagnosis, and the Endocrine Society advises against screening men without symptoms. [30], [31], [1], [7]

What testosterone level counts as low in older men?

This table shows each major clinical guideline's line, plus older definitions still quoted online, checked in September 2026. No body sets a separate line for older men, and all of them also require symptoms.

[4], [5], [7], [32], [6], [33], [3], [34], [35], [36], [37], [1], [22], [38], [17]

No body lowers the bar for age. North American bodies land at about 264–300 ng/dL, most European and international bodies at 12 nmol/L (about 350 ng/dL), and the UK Society for Endocrinology and the European Academy of Andrology use bands around 8–12 nmol/L. The real disagreement about older men is whether to treat, covered in should older men be treated? [7], [34], [27]

Doserly

Where guidelines draw the line for low testosterone

Total testosterone below which each body supports a diagnosis, with symptoms.

Each line runs from 200 ng/dL (7 nmol/L, left) to 400 ng/dL (14 nmol/L, right); the shaded part is 264–350 ng/dL, where the guidelines' lines fall. A dashed circle means an approximate line.

Endocrine Society (2018)

Below 264 ng/dL (9.2 nmol/L), standardized assays

CUA (Canada, 2021)

Below 10 nmol/L (about 290 ng/dL)

AUA (US, 2018, reconfirmed 2024)

Below 300 ng/dL (10.4 nmol/L)

Endocrine Society statement (July 2026)

“Near 300 ng/dL”

EAU · ICSM · BSSM (Europe 2026 · international 2024 · UK 2023)

Below 12 nmol/L (about 350 ng/dL)

Every guideline also requires symptoms, and all but the CUA call for at least two morning tests; none diagnoses from a number alone.

Why do the numbers differ?

• Lab methods. The 264 ng/dL line is the bottom 2.5% of healthy, non-obese men aged 19–39 on one calibrated scale, which is why it needs a CDC-certified assay. In another cohort measured by mass spectrometry, the bottom 2.5% sat at 348.3 ng/dL. [39], [40]
• Where benefit clusters. Some bodies drew their lines where symptoms and trial benefit gather; the UK Society for Endocrinology sees benefit mainly below 8 nmol/L and little above 12. [34]

Units. 1 nmol/L equals 28.84 ng/dL, so 12 nmol/L is about 346 ng/dL. The testosterone unit converter does the arithmetic.

Is there a "normal level for your age"?

Studies have published age-based ranges, but no current guideline uses a lower line for older men. "Normal for your age" describes how common a level is, not whether it explains symptoms.

• Proposed age limits. The Massachusetts Male Aging Study proposed lower limits of 251, 216, 196 and 156 ng/dL (8.7, 7.5, 6.8 and 5.4 nmol/L) for men in their 40s, 50s, 60s and 70s. No major guideline adopted them. [41]
• Very healthy older men. Australia's reference interval was 6.4–25.7 nmol/L in very healthy men aged 70–89, against 10.4–30.1 nmol/L in young men. [36]
• One line at any age. The Endocrine Society and the VA use the young-men line of 264 ng/dL. [5], [32]

The low testosterone guide has typical levels by decade.

Doserly

Age limits were proposed; guidelines kept one line

Lowest normal total testosterone proposed for each decade, against the guideline lines used at every adult age.

Each line runs from 100 ng/dL (left) to 400 ng/dL (right). The gold dot is the proposed age limit; the three dark ticks are the guideline lines at 264, 300 and about 346 ng/dL.

Proposed age limits (Massachusetts Male Aging Study, never adopted)

Men in their 40s

251 ng/dL (8.7 nmol/L)

Men in their 50s

216 ng/dL (7.5 nmol/L)

Men in their 60s

196 ng/dL (6.8 nmol/L)

Men in their 70s

156 ng/dL (5.4 nmol/L)

Guideline lines (the same at every adult age)

Endocrine Society 2018 and VA

264 ng/dL (9.2 nmol/L)

AUA; Endocrine Society 2026 statement

300 ng/dL (10.4 nmol/L); the 2026 statement says “near 300”

EAU, ICSM and BSSM

12 nmol/L (about 346 ng/dL)

The age limits describe how common a level is in healthy men; no major guideline adopted them, and the Endocrine Society says the diagnosis is the same at any age.

How should older men be tested?

The same rules apply after 60:

• Morning, even though the rhythm flattens. The morning peak is much smaller in healthy older men: afternoon levels were 20–25% lower than 8 am levels at 30–40, and about 10% lower at 70. Researchers and ISSAM still recommend morning samples at every age. [42], [43], [37]
• Fasting. In healthy older men, an overnight fast raised morning testosterone by 9–16%. [9]
• When well. Acute illness is one of the reversible causes to rule out first. [35]
• Twice, with a certified lab. [7]

See the low testosterone guide for the details.

Why do free testosterone and SHBG matter more with age?

Because the main carrier protein rises with age, total testosterone can look normal while the usable part falls. In the blood, about 2% of testosterone floats free, 53–55% is loosely bound to albumin and 43–45% is tightly bound to SHBG (sex hormone-binding globulin). [44]

• SHBG rises with age, about 2.3–2.5% a year in two Australian cohorts of older men. [45] Obesity pushes the other way, lowering SHBG so total testosterone can read low while free testosterone is normal. [46]
• Free testosterone tracked symptoms. Over 4.3 years in EMAS, 4.9% of men developed low total with normal free testosterone and 1.9% developed low total and low free testosterone. Only the second group developed new sexual symptoms. [47]

Guidelines measure free testosterone when SHBG is likely to be altered or total testosterone is borderline, by equilibrium dialysis or calculation, not with direct kits. Their lines are 220 pmol/L (EAU, with limited evidence), 225 pmol/L (BSSM) and 225–243 pmol/L (proposed by ISSAM). [5], [6], [3], [37]

Which other tests find the type and the cause?

LH and FSH, the pituitary's signals to the testes. High LH with low testosterone points to the testes (primary hypogonadism); low or normal LH points to the brain and pituitary (secondary hypogonadism). In EMAS, 11.8% of men aged 40–79 had the secondary pattern, 2.0% the primary pattern and 9.5% normal testosterone with a high LH (compensated hypogonadism). See primary vs secondary hypogonadism. [5], [48]

What causes late-onset hypogonadism?

A mix of ageing testes and everyday health problems that quiet the brain's signal, above all obesity. In EMAS, age went with lower free testosterone and a rising LH, the pattern of testes working less. A body mass index (BMI) of 30 or more went with total testosterone about 5.09 nmol/L lower without an LH rise, the pattern of a quieter signal from the brain. [49]

How fast does testosterone fall with age?

Slowly. In studies that followed the same men for years, total testosterone fell 1.6% a year in Massachusetts (and bioavailable testosterone, the easily used part, 2–3%), and 1.3% and 0.9% a year in two Australian cohorts. EMAS and a South Australian (Adelaide) study found smaller falls, about 0.1 nmol/L a year. [8], [45], [50], [10]

Low readings become common in later life even though the condition does not. In a Baltimore study, about 20% of men over 60, 30% over 70 and 50% over 80 had readings in the low range, counted by blood level alone. An Australian population showed a gradual fall from 35 and a steeper one after 80. [51], [52]

Is it ageing or health?

Both, and studies weigh them differently.

• Health explains much of it. A five-year Australian study concluded that the decline "is not inevitable but is largely explained by smoking behavior and intercurrent changes in health status, particularly obesity and depression". In men over 40 reporting very good health, average testosterone "did not vary with age". In Massachusetts, good health added 10–15% to androgen levels. [10], [9], [8]
• Age still counts. Levels fall a little each year in the same men and fall faster after 80. Older men were more likely to have the primary pattern (relative risk ratio 3.04), while obesity drove the secondary pattern (8.74). [45], [52], [48]

Which treatable problems lower testosterone in older men?

• Obesity and weight gain, the strongest driver of the secondary pattern. See obesity-related hypogonadism. [48]
• Type 2 diabetes. A third (33%) of men with type 2 diabetes in one study had low testosterone, mostly with low or normal LH. [53]
• Opioid painkillers. Men using opioids had total testosterone about 165 ng/dL lower than men who did not, and 63% had low testosterone in a review of 15 studies. [54], [55]
• Steroid (corticosteroid) tablets. [7]
• Sleep apnea, which travels with low testosterone mostly through weight; treating it with CPAP did not significantly raise testosterone (a pooled change of 1.08 nmol/L, too uncertain to count). [56]

Do not stop a prescribed opioid or steroid on your own: both need a supervised plan.

Is low testosterone in older men dangerous?

It is linked with a higher risk of death, but no study has shown that it causes those deaths or that treatment prevents them. In EMAS, men with severe late-onset hypogonadism died at about 5 times the rate of other men over a median of 4.3 years (hazard ratio 5.5). Men with three sexual symptoms died at about 3 times the rate, whatever their testosterone level. In the TRAVERSE trial, deaths were similar on testosterone gel and placebo: 144 of 2,596 men against 148 of 2,602. [57], [16]

Does late-onset hypogonadism go away?

Sometimes, especially the secondary kind. In EMAS, 42.9% of men with secondary hypogonadism returned to normal within about four years without treatment, more often without obesity, after weight loss (odds ratio 2.24), with a normal waist and under 60. Their symptoms did not improve at the same time. Free testosterone changed significantly only in men who lost or gained 15% or more of their weight. [58], [50]

How is late-onset hypogonadism usually treated?

Guidelines treat reversible causes first, treat the most bothersome symptom, and offer testosterone when symptoms and repeatedly low levels come together, not for ageing alone. This section describes the choices clinicians weigh; it is not a personal plan. [6], [5]

[6], [7], [27], [3], [5], [28], [4], [33], [59]

Should older men be treated at all?

This is where guidelines and regulators disagree most. Checked September 2026.

[5], [7], [6], [60], [24], [17], [19], [61], [38]

They weigh the same trials: clear gains in sexual function, bone density and anemia, little or none for energy, walking and memory, and more clots, rhythm problems and fractures (see the research). Bodies that stress the gains treat more symptomatic older men; bodies that stress the unknowns treat fewer. [15], [7]

How has the FDA's position changed?

Checked September 2026.

[62], [63], [64], [19], [65]

Until the labels change, the FDA's own page says none of the approved products "are approved for use in men with low testosterone levels who lack an associated medical condition". [25]

Should weight loss come first?

Most guidelines say yes when obesity is the driver; the BSSM and the AUA prefer both together.

• Weight loss first: the EAU (strong recommendation), the Endocrine Society's 2026 statement (BMI over 27) and the EAA. [6], [7], [27]
• Both together: the BSSM says "current evidence does not support the recommendation for lifestyle intervention alone as first-line therapy", and the AUA advises weight-loss programs alongside testosterone for overweight men. [3], [4]

Pooled studies found testosterone rose about 2.5–2.9 nmol/L after diet-based weight loss and 7.2–8.7 nmol/L after bariatric surgery. In a 16-week trial, liraglutide raised testosterone by 2.6 nmol/L with 7.9 kg of weight loss, against 5.9 nmol/L and 0.9 kg with testosterone gel. Testosterone itself is not a weight-loss treatment, the EAA and EAU add. [66], [67], [59], [27], [6]

Can the symptom be treated directly?

Often, and for erections it is usually the first step. In men with erectile dysfunction and low testosterone whose sildenafil dose was first optimized, adding testosterone gave no significant extra gain (2.2 points on the erectile function score, against 7.7 from sildenafil alone). The BSSM still suggests considering both together, particularly below 8 nmol/L or after erection tablets fail. [68], [3]

Which forms and levels do guidelines aim for in older men?

• Form. The EAU suggests gels rather than long-acting injections when starting in men at high risk, and the EAA prefers a transdermal form (absorbed through the skin). The American College of Physicians, looking at cost, suggested intramuscular injections (into a muscle). [6], [27], [60]
• Target. The AUA aims for 450–600 ng/dL, the Endocrine Society for mid-normal (350–600 ng/dL), the CUA for 14–17 nmol/L and the BSSM for 15–30 nmol/L. [4], [5], [35], [3]

Doses come from each medicine's label; see TRT dosage and the TRT dose calculator. Testosterone for women uses different products; see testosterone therapy for women.

How long is treatment, and when do guidelines stop it?

Most guidelines stop testosterone if symptoms have not improved by a review point: about 3 months (CUA), 3–6 months (AUA), 6 months (BSSM), 6–12 months (VA) or 12 months for sexual function (American College of Physicians). The UK Society for Endocrinology instead expects lifelong treatment once the diagnosis is confirmed. [35], [4], [3], [32], [60], [34]

Stopping is possible, but the body's own signal returns slowly: after two years of injections in the T4DM trial, LH and FSH recovered gradually over 12 months. See stopping TRT. [69]

What if you still want children?

Testosterone switches off sperm production, and labels warn reduced fertility may not reverse in some men. The AUA says not to prescribe it to men trying to conceive; hCG, clomiphene-type tablets or aromatase inhibitors can keep fertility. See TRT and fertility. [28], [4]

What does testosterone do for older men?

It helps sexual function, bone density and anemia most, lifts mood slightly, and does not improve energy, walking or memory. Most of this comes from controlled trials in older men, mostly using gels for one to three years. [15]

What did the Testosterone Trials find?

The Testosterone Trials gave 790 men aged 65 and older with testosterone under 275 ng/dL a year of testosterone gel or placebo; 51,085 men were screened to find them. [11]

[11], [14], [12], [13], [70], [71]

Men whose estradiol (the estrogen made from testosterone) rose more gained more sexual desire; see estrogen on TRT. [72]

What did other trials in older men find?

• TEAAM (308 men aged 60 and older, gel for 3 years): no difference in artery changes, sexual function or quality of life, and modest gains in stair-climbing power and muscle. The authors warned it "should not be interpreted as establishing cardiovascular safety". [73], [74]
• TOM (209 men aged 65 and older with limited mobility, average age 74): more men gained meaningful strength (43% against 18%), but walking speed, activity and fatigue did not change. It was stopped early after 23 men on testosterone and 5 on placebo had heart-related adverse events. [75], [76]
• TRAVERSE (men aged 45–80 at high heart risk): in 1,161 men with low sex drive, sexual activity and desire improved, but erections did not. It did not improve late-life low-grade depression (see TRT and mental health) or significantly prevent diabetes. [77], [78], [79]
• T4DM (1,007 men aged 50–74 with a large waist, injections plus a lifestyle program for 2 years): 12% had diabetes at 2 years against 21% on placebo. [80]
• Pooled trials (meta-analyses) in middle-aged and older men found about 1.6 kg less fat and 1.6 kg more lean mass, with no change in weight. Strength gains in men over 60 were small (Hedges g 0.21, a standard measure where 0.2 counts as small). Erectile function scores rose about 2 points regardless of age, and thinking skills did not change. [81], [82], [83], [84]

Where they disagree. Erections improved in the Testosterone Trials but not in TRAVERSE or TEAAM, and diabetes was prevented in T4DM (injections with a lifestyle program) but not in TRAVERSE (gel without one). The Endocrine Society advises against testosterone to control blood sugar. [79], [5]

Timing. Sex drive tends to improve from about 3 weeks, erections over up to 6 months and body composition over 12–16 weeks, which is why review points fall at 3–12 months. See how long TRT takes to work. [85]

What are the risks for older men?

Is testosterone therapy safe for older men?

For heart attacks and strokes over about two years, the largest trial found no increase, but it found more heart-rhythm problems, kidney injury, clots in the lungs and fractures, and long-term safety is not established. [16], [7]

What did TRAVERSE show about the heart?

TRAVERSE randomized about 5,200 men aged 45–80 with low testosterone and heart disease or high heart risk to daily testosterone gel or placebo gel. [16], [86]

• Heart attack, stroke or heart death: 7.0% on testosterone and 7.3% on placebo (182 of 2,596 men against 190 of 2,602; hazard ratio 0.96), meeting the trial's safety margin. [16]
• More common on testosterone: atrial fibrillation (an irregular heart rhythm) 3.5% against 2.4%, acute kidney injury 2.3% against 1.5%, and pulmonary embolism (a clot in the lungs) 0.9% against 0.5%. [17]
• Fractures: 3.50% against 2.46%. [18]
• Limits: only a daily gel, an average of 21.7 months of treatment, about 61% stopping their study gel early, and only men at high heart risk. [16], [17]

Doserly

TRAVERSE: absolute results

Testosterone gel (2,596 men)Placebo gel (2,602 men)

Heart attack, stroke or heart death

Testosterone 7.0% vs placebo 7.3% (182 vs 190 men; hazard ratio 0.96, 95% CI 0.78–1.17; met the 1.5 safety margin)

Nonfatal rhythm problems needing treatment

Testosterone 5.2% vs placebo 3.3%

Atrial fibrillation

Testosterone 3.5% vs placebo 2.4%

Clinical fracture

Testosterone 3.5% vs placebo 2.5% (91 of 2,601 vs 64 of 2,603 in the full analysis set)

Acute kidney injury

Testosterone 2.3% vs placebo 1.5%

Venous clots (all)

Testosterone 1.7% vs placebo 1.2%

Pulmonary embolism

Testosterone 0.9% vs placebo 0.5%

About 5,200 men aged 45–80 at high heart risk; daily gel; mean treatment 21.7 months; about 61% stopped their study gel. Not a trial of injections.

Before TRAVERSE, the signals pointed both ways. Besides TOM, a US veterans records study reported more events in treated men (25.7% against 19.9% at 3 years). Its figures were later corrected, and the uncertainty range crosses zero. Another study found heart attacks in the 90 days after a first prescription at about twice the prior year's rate in men 65 and older. Pooled earlier trials found cardiovascular events in 7.5% on testosterone and 7.2% on placebo. [76], [87], [88], [89]

The Endocrine Society's 2026 statement notes "roughly a 50% relative increase in pulmonary embolism" in TRAVERSE. The FDA has found that all testosterone products raise blood pressure. After a heart attack or stroke, the Endocrine Society waits 6 months before starting testosterone, the VA 4 months and the AUA 3–6 months. See TRT and heart health. [7], [62], [5], [32], [4]

What about the prostate?

Testosterone raises PSA a little, and long-term prostate cancer risk is not settled. In a 2005 review of 19 trials in men aged 45 and older, testosterone raised prostate events (odds ratio 1.78), mostly biopsies and PSA rises. In TRAVERSE, high-grade prostate cancer occurred in 0.19% on testosterone and 0.12% on placebo, not a significant difference. Men with a PSA above 3.0 ng/mL were not enrolled. The AUA checks PSA before starting in men over 40, and the Endocrine Society refers men to a urologist if PSA rises by more than 1.4 ng/mL in the first year. [90], [86], [4], [5]

Checked September 2026. US labels do not allow testosterone with known or suspected prostate cancer. The FDA's June 2026 request to narrow this to cancer that has spread is not yet in the labels, and Health Canada opened its own review in May 2026. See TRT and the prostate. [24], [19], [91]

What other risks matter more with age?

• Red blood cells. In the same 2005 review, men on testosterone were nearly four times as likely to have a hematocrit above 50% (odds ratio 3.69). In T4DM, 22% of men on testosterone injections passed 54%, against 1% on placebo. See hematocrit on TRT. [90], [80]
• Fractures. Despite higher bone density, fractures were not prevented in TRAVERSE, and a 2026 review found more clinical fractures (risk ratio 1.55), though not more hip or spine fractures. [18], [92]
• Sleep apnea. In men with obesity and severe sleep apnea, testosterone injections worsened nighttime oxygen drops at 7 weeks, though not at 18 weeks. [93]
• Fluid retention, a concern with heart, kidney or liver disease. [94]

Who should be especially cautious?

Guidelines list different reasons not to start:

• The Endocrine Society: plans for children soon; breast or prostate cancer, a prostate lump, or a PSA above 4 ng/mL without a urologist's review; a high hematocrit; untreated severe sleep apnea; severe urinary symptoms; uncontrolled heart failure; a heart attack or stroke in the last 6 months; or an inherited clotting tendency. [5]
• The VA adds a blood clot without a clear cause, severe liver disease or kidney failure, and current anabolic steroid misuse. [32]
• The EAU adds a family history of clots and a baseline hematocrit of 48–50% as reasons for caution. [6]
• Older men with limited mobility and many health problems, the group in which TOM stopped early; drug-tested athletes (see legal status); and under-18s, for whom testosterone belongs only in specialist care. [76]
• Women. This guide is written for men; see testosterone therapy for women.

Which medicines interact with testosterone?

Older men often take several medicines. US labels list four interactions: insulin and other diabetes medicines (testosterone can lower blood sugar), blood thinners taken by mouth such as warfarin (clotting tests need closer checks), corticosteroids (more fluid retention), and other medicines that raise blood pressure. An EU safety review in 2025 also recommended warning that SGLT2 inhibitor diabetes medicines add to the rise in hematocrit. Bring a complete list, including supplements, to a pharmacist or prescriber. Checked September 2026. [24], [17], [94], [95]

Is testosterone legal, and is it allowed in sport?

Checked September 2026. Rules differ by country and change often.

• United States. Testosterone and its esters are Schedule III controlled substances, prescription only; no proposal to change that has been published. [20]
• United Kingdom. Testosterone is a Class C controlled drug under the Misuse of Drugs Act 1971, and in Schedule 4 Part II of the Misuse of Drugs Regulations 2001. [96], [97]
• Canada. Testosterone is a Schedule IV controlled substance. [98]
• Australia. Testosterone is a Schedule 4 prescription-only medicine. [99]
• Sport. The World Anti-Doping Agency (WADA) prohibits testosterone at all times, and its 2027 list keeps the ban. An exemption is granted only for low testosterone from a disease of the testes or pituitary, not for functional causes such as ageing. [21], [100], [101]

For access and cost, see the country guides for the United States, the United Kingdom, Canada, Australia and Europe.

What do people in public communities report?

Many public posts from men over 40 describe a result near the line and a doctor who calls it normal. The threads below are recent public Reddit discussions, read with their replies; they show what people go through, not how often it happens.

"My doctor says it is normal for my age"

A frequent complaint. A man of 67 who had lost muscle during a large weight loss measured 300 ng/dL and was told his level was normal for his age. A man of 60 measured 193 ng/dL after losing about 50 pounds on a weight-loss medicine and was told it was part of aging; a clinic later prescribed testosterone. A man of 40 measured 265 ng/dL, against 316 ten years earlier, and was told it was within the lab's range. [102], [103], [104]

Some of these results sit above one guideline's line and below another's, exactly where the key numbers disagree. A man of 50 in the UK measured 10 nmol/L, inside his lab's range of 8–30, and his public health service would not treat him. [105]

What if total testosterone is normal but free is low?

A recurring pattern. A man of 50 with a total of 770 ng/dL had an SHBG of 85.8 nmol/L, a low free testosterone, low libido and weaker erections; several replies urged an endocrinologist's review before treatment. A man of 40 had severe erection problems despite tadalafil. He had a total of 20.0 nmol/L on two morning tests, an SHBG of 53 nmol/L and a calculated free testosterone near the bottom of his lab's range. [106], [107]

Did weight loss change the number?

Sometimes dramatically. A man of 41 who deferred a testosterone prescription measured 144 ng/dL at 498 pounds and 625 ng/dL at 302 pounds, and felt much stronger; he had also had untreated sleep apnea. Others saw the number rise but not the symptoms. After losing about 8% of his weight and starting CPAP, a man of 41 rose from 11.9 to 21.9 nmol/L but still felt exhausted and without sex drive. [108], [109]

Is it a lifelong commitment?

This worry stops many men. A man of 54 with three monthly results of 204, 327 and 241 ng/dL wrote that the lifelong part "truly feels like a one-way ticket"; replies pointed out that men do stop. A man of 43 at 10.8 nmol/L feared starting something he could not reverse, and his hematocrit was already 53% before any treatment, which replies flagged. Guidelines differ here too (see how long). [110], [111]

What do older men report after starting?

Every direction:

• Better. A man of 55 who lost 19 kg and had his thyroid treated first described much higher libido and daily morning erections at six weeks. He had started at 21.5 nmol/L, above every guideline line in this guide, which replies raised. [112]
• Better, with a lab problem. A man of 57 felt gel "did nothing" for a year, switched to injections and reached 1,800 ng/dL before his dose was cut. A year in he reported better energy, fitness and sex life, but poor sleep and a hematocrit of 0.55 (55%). [113]
• Not better. A man of 49 who started at 350 ng/dL was "unimpressed" at 12 weeks: erections and libido were still poor even with erection tablets, and his ankles swelled. [114]
• Too high. A man of 64, five years on treatment, moved to twice-weekly injections with a second prescriber and measured 2,030 and then 2,593 ng/dL, far above any target. His primary care doctor said it was too high, and he began cutting back. [115]

How can you judge a late-onset story?

Ask: Were there two morning, fasting results, in which units? Were free testosterone, SHBG and LH measured? Was the man dieting, sleeping badly, ill or taking opioids, steroids or a weight-loss medicine at the time? Was his level on treatment within the guideline targets? And what did the next six months show?

These selected discussions show what people experience. They are not a survey of all men with late-onset hypogonadism, a success rate or a substitute for the studies above.

What should you track?

Before a diagnosis: symptoms, weight and every result with its date, time and fasting status. On treatment: usually testosterone and hematocrit at 3–6 months and 12 months, then yearly (the EAU at 3, 6 and 12 months), plus PSA. Use this to prepare questions; it is not a personal testing plan. [5], [6]

[22], [4], [3]

Time of day, food, weight change and the lab all move the reading, so a trend of morning results drawn under similar conditions says more than any one number. See TRT blood work. [43], [9]

Common questions about late-onset hypogonadism

What is a normal testosterone level for a man my age?

There is no official age-adjusted cut-off. Researchers proposed lower limits falling from 251 ng/dL in the 40s to 156 ng/dL in the 70s. Guidelines use one line at every adult age: about 264–300 ng/dL in North America and 12 nmol/L (about 350 ng/dL) in Europe. [41], [7], [6] See normal for your age.

Should men over 65 take testosterone?

Only when symptoms and repeatedly low morning levels come together, most guidelines say. The Endocrine Society advises against treating all men 65 and older routinely, the EAU against testosterone for vitality or strength, and the American College of Physicians' 2020 guideline (now inactive) limited it to sexual problems. [5], [6], [60] See should older men be treated?

Is testosterone FDA-approved for age-related low testosterone?

Not as of September 2026. US labels still say its safety and effectiveness in "age-related hypogonadism" have not been established. The FDA asked makers to remove that limitation on 18 June 2026, but it is not yet in any label. [17], [19], [65] See the FDA timeline.

Does late-onset hypogonadism go away on its own?

Sometimes. In EMAS, 42.9% of men with the secondary kind returned to normal within about four years without treatment, more often after weight loss, although their symptoms did not improve at the same time. [58] See does it go away?

Will testosterone help my energy or memory?

Probably not. In the largest trial in men aged 65 and older, a year of testosterone gel did not improve energy, walking or memory, while it improved sexual function and mood slightly. [11], [14], [15] See the Testosterone Trials.

What is the ICD-10 code for late-onset hypogonadism?

It has no code of its own. In the US version of the classification, the closest code is E29.1 (testicular hypofunction). Pituitary causes fall under E23.0, and N46.8 is a male infertility code. [116]

Glossary

Plain explanations of the medical, lab and research terms used in this guide. Underlined terms in the text link here.

Andropause ("male menopause")

An informal name for age-related low testosterone. Guidelines avoid it, because testosterone in most men falls slowly rather than stopping as it does in menopause.

CDC-certified assay

A testosterone test that has passed the US Centers for Disease Control and Prevention's standardization program, so its results match other certified labs. Guideline cut-offs such as 264 ng/dL assume a certified test.

Compensated hypogonadism

Normal testosterone with a high LH, as if the pituitary is working harder to keep testosterone up. Its meaning is unclear, and it is usually watched rather than treated.

Controlled trial

A study that compares people who receive a treatment with a similar group who do not, often receiving a placebo instead. Randomly assigning people to each group makes the comparison fairer.

CPAP

Continuous positive airway pressure: a bedside machine that blows air through a mask to keep the airway open during sleep. It is the standard treatment for obstructive sleep apnea.

EMAS (European Male Ageing Study)

A study of 3,369 men aged 40–79 in eight European centers that defined strict late-onset hypogonadism and followed how testosterone changes with age, weight and health.

Free testosterone

The small share of testosterone, about 2%, that is not attached to any protein in the blood. It is measured or calculated when SHBG is unusual or total testosterone is borderline.

FSH (follicle-stimulating hormone)

A pituitary hormone that acts on the cells supporting sperm production. Testosterone therapy lowers it.

Functional hypogonadism

Low testosterone from causes that can reverse, such as obesity, illness or some medicines, rather than a permanent disease of the testes or pituitary.

Clinical guideline

Recommendations written by a medical society or health system, based on its review of the evidence and expert judgment. Different guidelines can reach different conclusions.

Hazard ratio

A measure comparing how often an event happens over time in two groups. A hazard ratio of 1 means no difference; 0.96 means about 4% lower in the first group.

Hematocrit

The share of the blood made up of red blood cells. Testosterone raises it, and most guidelines act when it reaches about 54%.

Hypogonadism

Low testosterone caused by a problem in the testicles or in the brain and pituitary signals that control them, confirmed with symptoms and repeated morning blood tests.

Intramuscular (IM)

Injected into a muscle. Most testosterone cypionate and enanthate is given this way.

Product label (prescribing information)

The official document approved by a medicines regulator for a product, describing its approved uses, doses, warnings and monitoring.

LH (luteinizing hormone)

A pituitary hormone that tells the testicles to make testosterone. Testosterone therapy switches it off.

Limitation of Use

A line in a US drug label saying a use has not been shown to be safe or effective. Testosterone labels carry one for age-related hypogonadism; it is a caution, not a ban.

Meta-analysis and systematic review

A systematic review gathers all studies on a question in a planned way. A meta-analysis combines their results statistically.

Odds ratio

A measure comparing the odds of an outcome in two groups. An odds ratio of 2 means roughly twice the odds; 1 means no difference.

PDE5 inhibitor

A group of erectile dysfunction tablets, including sildenafil (Viagra) and tadalafil (Cialis), that improve blood flow to the penis.

Placebo

A dummy treatment with no active ingredient, used as a comparison in studies.

Primary hypogonadism

Low testosterone because the testicles themselves do not work well, even though the pituitary sends plenty of LH and FSH.

PSA (prostate-specific antigen)

A protein made by the prostate, measured in a blood test. It rises with prostate enlargement, inflammation and cancer, and a little on testosterone therapy.

Secondary hypogonadism

Low testosterone because the brain and pituitary send too little LH and FSH to the testicles. Also called hypogonadotropic hypogonadism.

SHBG (sex hormone-binding globulin)

A blood protein that carries testosterone. Testosterone bound to it is not immediately available to tissues, so SHBG affects how much free testosterone there is.

Obstructive sleep apnea

Repeated blocking of the airway during sleep, causing pauses in breathing and drops in oxygen. Loud snoring and daytime sleepiness are common signs.

Testosterone Trials (T Trials)

Seven coordinated US trials in 790 men aged 65 and older with low testosterone, comparing a year of testosterone gel with placebo on sexual function, walking, energy, mood, memory, bone, anemia and heart arteries.

Transdermal

Absorbed through the skin, as with testosterone gels and patches.

TRAVERSE

A large trial of about 5,200 men aged 45–80 with low testosterone and heart disease or high heart risk, comparing daily testosterone gel with placebo gel for heart safety.

TRT (testosterone replacement therapy)

Prescribed testosterone, by injection, gel or other forms, for men with low testosterone. It switches off the brain's LH and FSH signals.

WADA

The World Anti-Doping Agency, which publishes the list of substances banned in sport. Testosterone is banned at all times.

How this guide was researched

This guide is built from a thorough review of the sources cited throughout it: clinical guidelines and recommendations from 15 medical bodies, product labels, published clinical trials and population studies, and regulatory documents from the US, Europe, Canada and Australia. We also reviewed public online forums where men over 40 describe their own test results, treatment decisions and experiences.

The guide cites 116 sources, including 48 original studies in people, 16 clinical guidelines and position statements, and 14 public community discussions. Each type of source answers a different question. Guidelines and labels show what clinicians are told to do. Trials and population studies show what was measured. Personal accounts show what individual people experienced. Every numbered citation links to its entry below, labeled by source type.

How this guide was made

Research and drafting were AI-assisted. Every cited source was checked against the original, and the guide was reviewed and edited by Doserly before publication. It has not had an independent clinical review, and Doserly does not currently have medical reviewers. Doserly makes a medication and health-tracking app and runs Doserly Academy, both of which are promoted in this guide. Read our editorial policy for how guides are researched, updated and corrected.

This guide is for educational purposes. It summarizes what the reviewed sources report so the research is easier to understand; it is not medical advice. For a deeper dive, or to check any point for yourself, go straight to the cited sources.

Explore the sources